查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1922985

结核病市场按药物类别、检测类型、治疗方法、最终用户和分销管道划分－全球预测（2026-2032 年）

Mycobacterium Tuberculosis Market by Drug Class, Test Type, Treatment Regimen, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，结核病市场价值将达到 40.8 亿美元，到 2026 年将成长到 43.3 亿美元，到 2032 年将达到 65.2 亿美元，年复合成长率为 6.91%。

主要市场统计数据
基准年 2025 40.8亿美元
预计年份：2026年 43.3亿美元
预测年份：2032年 65.2亿美元
复合年增长率 (%) 6.91%

本文简要概述了构成现代结核病控制方法的临床、诊断和公共卫生方面的内容。

由于复杂的生物学、社会和卫生系统因素，结核分枝桿菌感染仍然是全球面临的健康挑战。该病原体建立潜伏感染的能力、多样化的临床表现以及抗药性菌株的出现（这些都使治疗途径更加复杂）持续影响临床管理。诊断演算法和治疗通讯协定正在不断发展，以平衡敏感性、速度和可及性，而公共卫生计画则致力于将预防、病例发现和持续护理整合到资源有限的卫生系统中。

快速诊断、治疗方法创新、供应链韧性和以患者为中心的医疗服务如何重塑全球结核病诊疗管道

结核病防治格局正经历着由技术进步、政策调整和患者照护模式演变所驱动的变革。分子诊断平台能够提供快速检测和抗药性分析，从而加快诊断速度，实现早期治疗性介入和更精准的治疗选择。同时，照护现场和近乎专利期的检测技术正在推动任务转移和去中心化，减少对中心检查室的依赖，并扩大偏远地区的医疗服务覆盖范围。

了解2025年美国关税如何改变了结核病诊断和治疗生态系统内的供应链、采购行为和策略性生产决策。

主要经济体征收进口关税和采取贸易措施，对诊断和治疗价值链产生连锁反应，影响供应、筹资策略和营运成本。鑑于美国将于2025年实施关税，诊断设备製造商、药品经销商和医疗系统等相关人员被迫重新评估其筹资策略和合约谈判。依赖关税进口的诊断设备、耗材和品牌治疗药物面临到岸成本上涨的压力，影响机构和国家层级的采购决策。

以细分市场主导的洞察，将诊断应用、治疗层级趋势、治疗方法、用户环境和分销管道与营运重点联繫起来。

观点既定的市场区隔方法分析市场，可以发现诊断和治疗管道存在着不同的需求和机会。在考虑药物类别时，第一线药物和二线药物之间的差异仍然至关重要。第一线疗法对于治疗药物敏感性疾病和维持治疗方案的成功至关重要，而二线药物则用于治疗抗药性病例，并需要加强对不利事件和疗效的监测。这些趋势会影响采购週期、库存管理和临床医生培训的重点。

区域观点：揭示流行病学、基础设施、政策框架和私营部门趋势如何独特地影响重点区域的结核病防治规划优先事项

区域动态影响结核病防治计画介入措施的优先顺序和资源分配，各大区域的流行病学、卫生基础设施和计画环境均有差异。在美洲，拥有先进检测网路的高资源都市区与集体爆发，使得有针对性的筛检工作和具有文化敏感性的依从性策略变得尤为重要。公私部门合作以及与爱滋病防治服务的整合，对于提高病例发现率和确保全部区域医疗服务的连续性仍然至关重要。

结核病诊疗、治疗、製造和数位健康领域的策略性公司趋势正在推动结核病治疗领域的互通性、可负担性和伙伴关係。

诊断和製药领域的公司策略正朝着几个通用的主题靠拢：促进平台互通性、优化单次检测和治疗疗程的成本，以及建立伙伴关係以加速在重点地区的市场进入。诊断公司正在投资基于试剂盒的分子诊断系统、简化样本製备流程以及实现结果整合到临床工作流程中的连接性。製药和生物技术公司正在开发伴随诊断，以实现治疗方案优化、安全性评估以及针对抗药性疾病的个人化治疗。

为产业领导者提供切实可行的策略行动，以加速诊断分散化、增强供应韧性、加强监管合作、推动数位整合并促进实证医学的产生。

产业领导者应推动一系列协调一致的行动，在控制营运风险的同时提升影响力。优先推进快速分子诊断的去中心化，并确保强有力的培训和品质保证，将有助于扩大病例发现范围，缩短患者接受适当治疗的时间。同时，投资于区域製造伙伴关係和多元化的供应商网络，将增强企业应对贸易中断和关税造成的成本波动的能力。

以证据为导向的研究途径：整合相关人员访谈、文献回顾、资料三角验证和区域地图绘製，以确保研究结果的严谨性和相关性。

本分析的调查方法融合了多种定性和定量方法，旨在得出可靠且可操作的见解。主要资料收集包括对临床专家、检查室主任、采购负责人和卫生专案经理进行结构化访谈，以了解技术应用的操作实务和观点。次要研究包括对同行评审文献、临床指南和政策文件进行系统性回顾，以阐明临床管道和法规结构的背景。

技术进步与系统层面的准备工作相结合，迫切需要采取实际行动来缩小诊断差距、保障医疗服务并增强专案韧性。

本分析得出的LED结论指出，亟需采取实际的行动。弥合诊断差距、维持治疗效果以及增强卫生系统的适应能力是改善结核病治疗效果的核心。快速分子诊断和更短、更安全的治疗方法为降低发病率和加速患者康復提供了切实的机会，但要充分发挥这些潜力，必须加大对人力资源开发、品管系统和供应链韧性的投入。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章 美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

8. 按药物类别分類的结核病市场

  • 一线药物
  • 二线药物

9. 按检测类型分類的结核病市场

  • 培养试验
  • 干扰素γ释放试验
  • 显微镜
  • 分子检测
    • LAMP方法
    • PCR
    • Xpert Mtb Rif
  • 皮肤测试

10. 按治疗方法的结核病市场

  • 抗药性治疗
    • 广域电阻
    • 多重抗药性
  • 药物敏感性治疗

第十一章 依最终用户分類的结核病市场

  • 诊所
  • 医院
  • 检查机构
  • 研究所

第十二章 结核病市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十三章 各地区结核病市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 结核病市场（依群体划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国结核病市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国结核病市场

第十七章：中国的结核病市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Molecular Inc.
  • Actiza Pharmaceutical Private Limited
  • Anuh Pharma Ltd.
  • AstraZeneca PLC
  • Bayer AG
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Cadila Healthcare Ltd.
  • CapitalBio
  • Care Formulation Labs Private Limited
  • Cepheid, Inc.
  • Cipla Ltd.
  • DaAN Gene Company
  • Eiken Chemical Co., Ltd.
  • GlaxoSmithKline plc
  • Hain Lifescience GmbH
  • Hetero Labs Ltd.
  • Hologic, Inc.
  • Johnson & Johnson
  • Lupin Limited
  • Macleods Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Molbio Diagnostics Private Limited
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • QIAGEN NV
  • Roche Diagnostics International AG
  • Sandoz International GmbH
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Thermo Fisher Scientific Inc.
  • Titan BIoTech Limited
  • Viatris Inc.
Product Code: MRR-867BED9A9EA2

The Mycobacterium Tuberculosis Market was valued at USD 4.08 billion in 2025 and is projected to grow to USD 4.33 billion in 2026, with a CAGR of 6.91%, reaching USD 6.52 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.08 billion
Estimated Year [2026] USD 4.33 billion
Forecast Year [2032] USD 6.52 billion
CAGR (%) 6.91%

A concise orientation to the clinical, diagnostic, and public health dimensions that define contemporary approaches to Mycobacterium tuberculosis management

Mycobacterium tuberculosis remains a persistent global health challenge driven by complex biological, social, and health system factors. Clinical management continues to be shaped by the pathogen's ability to establish latent infection, variable clinical presentations, and the growing prevalence of drug-resistant strains that complicate therapeutic pathways. Diagnostic algorithms and treatment protocols have evolved to balance sensitivity, speed, and accessibility, while public health programs strive to integrate prevention, case-finding, and continuity of care into constrained health systems.

Contemporary attention focuses on closing diagnostic gaps, shortening treatment duration, and preserving the efficacy of existing antimicrobials. Advances in molecular diagnostics and digital health platforms have introduced new opportunities to decentralize testing and accelerate clinical decision-making, yet barriers remain around cost, supply chain resilience, and workforce capacity. Concurrently, treatment innovation has delivered new regimens and drug combinations that improve outcomes for resistant disease, but equitable access and adherence support are required to translate efficacy into population-level impact.

As stakeholders across clinical, laboratory, policy, and commercial domains align priorities, coordinated strategies that emphasize diagnostics-treatment integration, strengthened surveillance for resistance, and targeted investment in underserved settings will be essential to make measurable progress. This introduction outlines the biological context, current practice contours, and the strategic inflection points shaping how healthcare systems and industry partners respond to tuberculosis today.

How rapid diagnostics, therapeutic innovation, supply chain resilience, and patient-centered delivery are reshaping tuberculosis care pathways globally

The landscape of tuberculosis control is experiencing transformative shifts driven by technological progress, policy recalibration, and evolving patient care models. Molecular diagnostic platforms that offer rapid detection and resistance profiling have accelerated diagnostic turnaround, enabling earlier therapeutic intervention and more precise treatment selection. At the same time, point-of-care and near-patient testing technologies are enabling task shifting and decentralization, which reduces dependence on central laboratories and expands access in peripheral settings.

Therapeutic innovation has introduced novel agents and shorter regimens that are redefining treatment paradigms for drug-resistant disease. These advances interact with strengthened antimicrobial stewardship frameworks and more granular resistance surveillance to inform regimen selection and preserve drug efficacy. Parallel developments in digital health-such as electronic adherence monitoring, telehealth-enabled consultations, and integrated case management systems-are enhancing continuity of care and creating data streams that support programmatic decision-making.

Supply chain resilience and strategic manufacturing investments have become priorities in response to geopolitical shifts and procurement volatility, prompting stakeholders to diversify sourcing and develop regional capacity. Meanwhile, increased emphasis on patient-centered models and social determinants of health is reshaping service delivery, recognizing that diagnostics and therapeutics must be coupled with adherence support, nutritional assistance, and socioeconomic interventions to realize durable outcomes.

Understanding how United States tariff measures initiated in 2025 have altered supply chains, procurement behaviors, and strategic manufacturing decisions within tuberculosis diagnostics and therapeutics ecosystems

The introduction of import tariffs and trade measures by major economies can reverberate across diagnostic and therapeutic value chains, affecting availability, procurement strategies, and operational costs. In the context of tariffs implemented by the United States in 2025, stakeholders across diagnostics manufacturers, pharmaceutical distributors, and health systems have had to reassess sourcing strategies and contract negotiations. Equipment-dependent diagnostics, consumables, and branded therapeutics exposed to tariffed imports face upward pressure on landed costs, which in turn influences purchasing decisions at institutional and national levels.

Consequently, procurement agencies and manufacturers have pursued a mix of mitigation strategies, including nearshoring production, qualifying alternative suppliers, and accelerating regional manufacturing partnerships to reduce exposure to tariff-related volatility. For some health programs, these adjustments have introduced delays in onboarding new technologies or replenishing stock, particularly where regulatory approvals and quality assurance processes are localized. At the same time, tariff-driven cost pressures have incentivized suppliers to optimize product design for lower-cost consumables and to explore bundled service agreements that smooth procurement cycles.

Moving forward, the interplay between trade policy and public health highlights the importance of diversified supplier networks, collaborative procurement mechanisms, and forward-looking contracting that anticipates policy shifts. For clinical programs, maintaining continuity of high-quality diagnostics and treatment supplies requires active engagement with procurement experts, investment in local manufacturing where feasible, and adaptive inventory management to buffer against episodic supply disruptions.

Segment-driven insights that link diagnostic modality adoption, therapeutic class dynamics, treatment regimens, user settings, and distribution channels to operational priorities

Examining the market through established segmentation lenses reveals differentiated needs and opportunities across diagnostic and treatment pathways. When considering drug class categories, the distinction between first-line and second-line agents remains pivotal: first-line therapies are central to treating drug-susceptible disease and sustaining programmatic success, while second-line drugs drive clinical strategies for resistant cases and require enhanced monitoring for adverse events and efficacy. These dynamics influence procurement cycles, stock management, and clinician training priorities.

Test type segmentation underscores the coexistence of legacy and emerging diagnostic modalities. Culture-based assays and microscopy retain roles in clinical confirmation and resource-limited settings, while interferon gamma release assays and skin testing occupy niche roles in latent infection screening. Molecular tests, encompassing loop-mediated isothermal amplification, polymerase chain reaction platforms, and cartridge-based assays that detect both pathogen presence and rifampicin resistance, are increasingly central to rapid case detection and appropriate regimen initiation. The distribution of testing modalities across clinical pathways dictates laboratory investment, personnel upskilling, and quality assurance frameworks.

Treatment regimen segmentation differentiates strategies for drug-susceptible and drug-resistant disease, with multidrug-resistant and extensively drug-resistant categories requiring specialized therapeutic oversight and often prolonged care coordination. End user segmentation-spanning clinics, hospitals, laboratories, and research institutes-reflects varied capabilities, utilization patterns, and procurement authorities, which in turn shape demand for point-of-care versus centralized solutions. Distribution channel segmentation, covering hospital pharmacies, online pharmacies, and retail pharmacies, highlights evolving access models and underscores the need for regulatory clarity, inventory traceability, and patient counseling across diverse points of dispensation.

Together, these segmentation perspectives inform where investments in diagnostics, therapeutics, training, and supply chain improvements will yield the greatest operational and clinical returns. The intersection of molecular testing capacity with empowered end users and adaptive distribution channels presents the most immediate opportunity to reduce diagnostic delay and improve linkage to appropriate regimens.

Regional perspectives that reveal how epidemiology, infrastructure, policy frameworks, and private sector dynamics uniquely shape tuberculosis program priorities across major geographies

Regional dynamics shape how tuberculosis programs prioritize interventions and allocate resources, with distinct epidemiology, health infrastructure, and policy environments across major geographies. In the Americas, heterogeneity is pronounced between high-resource urban centers with advanced laboratory networks and lower-resource or remote communities that experience barriers to access. Migratory flows and concentrated outbreaks in vulnerable populations necessitate targeted screening initiatives and culturally tailored adherence strategies. Public-private engagement and integration with HIV services remain central to improving case detection and continuity of care across the region.

The Europe, Middle East & Africa constellation encompasses a broad range of settings from advanced public health systems to fragile states where conflict and displacement complicate service delivery. In parts of Africa, high burden and limited laboratory capacity create urgent need for decentralized molecular diagnostics and strengthened supply chains. Meanwhile, countries in Europe and the Middle East focus on surveillance for imported resistance, sustaining treatment adherence among diverse populations, and aligning regulatory pathways to expedite access to newer therapeutics.

Asia-Pacific carries the largest absolute clinical burden and demonstrates rapid uptake of new diagnostics and treatment approaches in several large health systems. National programs in high-burden countries are innovating with public-private mix models, leveraging digital adherence tools, and scaling molecular testing while contending with complex market dynamics in the private sector. Regional manufacturing hubs and active clinical research networks also create opportunities for localized production and evidence generation, which can shorten the translation period between trial results and policy adoption.

Strategic corporate moves across diagnostics, therapeutics, manufacturing, and digital health that are driving interoperability, affordability, and partnerships in tuberculosis care

Corporate strategies across diagnostics and pharmaceutical segments have converged on a few consistent themes: advancing platform interoperability, optimizing cost per test or treatment course, and forging partnerships that accelerate market access in priority settings. Diagnostics firms are investing in cartridge-based molecular systems, simplified sample preparation, and connectivity features that integrate results into clinical workflows. Pharmaceutical manufacturers and biotech players are pursuing regimen optimization, safety profiling, and companion diagnostics that enable personalized approaches for resistant disease.

Collaboration between diagnostic vendors and drug developers is increasingly common, motivated by the need to align rapid resistance detection with timely therapeutic decisions. Contract manufacturing organizations and regional producers have become strategic partners for multinational firms seeking to mitigate supply chain risk and improve lead times. Meanwhile, companies offering digital health solutions and adherence technologies are positioning their products as complementary to diagnostics and therapeutics, emphasizing outcomes-based value propositions to payers and programs.

Competitive dynamics also include pricing pressure from procurers and reimbursement agencies, which drives a focus on cost-effectiveness and long-term total cost of care. Investment in post-market evidence generation, real-world effectiveness studies, and implementation research supports product adoption and informs clinical guidelines. Overall, corporate actions are converging on scalable, integrated solutions that reduce diagnostic delay, simplify treatment delivery, and improve traceability across distribution channels.

Practical, strategic actions for industry leaders to accelerate diagnostic decentralization, supply resilience, regulatory collaboration, digital integration, and evidence generation

Industry leaders must pursue a set of coordinated actions to advance impact while managing operational risk. Prioritizing decentralization of rapid molecular diagnostics and ensuring robust training and quality-assurance frameworks will expand case detection and reduce time to appropriate therapy. Simultaneously, investing in regional manufacturing partnerships and diversified supplier networks will strengthen resilience against trade disruptions and tariff-driven cost volatility.

Strengthening collaborations with national programs and regulatory authorities can streamline approval pathways and enable adaptive procurement models that respond to epidemiological shifts. Leaders should integrate digital health tools that support adherence, outcome monitoring, and data-driven program management, thereby creating closed-loop systems that link diagnosis to sustained treatment completion. Pricing strategies must balance affordability and sustainability, with tiered approaches and outcome-based contracting explored where feasible.

Finally, committing to implementation research and real-world evidence generation will accelerate policy adoption and inform iterative improvements in product design and service delivery. Cross-sector partnerships that include civil society, patient advocacy groups, and payers will be essential to design equitable access programs and to ensure that innovations translate into population-level reductions in morbidity and mortality.

An evidence-driven research approach integrating stakeholder interviews, literature synthesis, data triangulation, and regional mapping to ensure rigor and relevance in insights

The research methodology underpinning this analysis integrates multiple qualitative and quantitative approaches to ensure robust, actionable findings. Primary data collection included structured interviews with clinical experts, laboratory directors, procurement officers, and health program managers to capture operational realities and perspectives on technology adoption. Secondary research involved systematic review of peer-reviewed literature, clinical guidelines, and policy documents to contextualize clinical pathways and regulatory frameworks.

Data triangulation techniques were applied to reconcile differences across sources, while thematic analysis identified recurring barriers and enablers related to diagnostics, treatment regimens, and distribution. Segmentation schemas were mapped to end-user capabilities and procurement modalities to surface targeted insights for stakeholders operating at clinic, hospital, laboratory, and research institute levels. Regional analyses accounted for epidemiologic patterns, infrastructure maturity, and policy environments to ensure relevance across diverse settings.

Quality assurance measures included cross-validation of interview findings with documented program reports and iterative peer review by subject-matter experts. Ethical considerations were observed in primary engagements, ensuring confidentiality and informed consent. The result is an evidence-informed synthesis that emphasizes operational feasibility, adoption barriers, and strategic levers for improving tuberculosis detection and treatment pathways.

Converging technological advances and system-level preparedness create a practical imperative to close diagnostic gaps, protect therapeutics, and strengthen program resilience

The conclusions drawn from this analysis underscore an urgent yet actionable agenda: closing diagnostic gaps, preserving therapeutic efficacy, and strengthening health system adaptability are central to improving tuberculosis outcomes. Rapid molecular diagnostics and shorter, safer treatment regimens offer tangible opportunities to reduce morbidity and accelerate patient recovery, but realizing their potential requires coordinated investments in workforce capacity, quality systems, and supply chain resilience.

Trade policy shifts and procurement volatility underscore the need for diversified sourcing and regional manufacturing partnerships to sustain access to essential diagnostics and medicines. Equally important is the integration of clinical services with digital tools that support adherence and enable real-time surveillance for resistance patterns. Collective action across private industry, public health authorities, and civil society will be necessary to translate technological advances into equitable access and measurable public health gains.

In sum, the evolving tuberculosis landscape presents both challenges and opportunities: by aligning innovation with pragmatic implementation strategies, stakeholders can converge on solutions that improve detection, optimize treatment, and strengthen long-term resilience of TB programs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Mycobacterium Tuberculosis Market, by Drug Class

  • 8.1. First Line Drugs
  • 8.2. Second Line Drugs

9. Mycobacterium Tuberculosis Market, by Test Type

  • 9.1. Culture Tests
  • 9.2. Interferon Gamma Release Assays
  • 9.3. Microscopy Tests
  • 9.4. Molecular Tests
    • 9.4.1. Lamp
    • 9.4.2. Pcr
    • 9.4.3. Xpert Mtb Rif
  • 9.5. Skin Tests

10. Mycobacterium Tuberculosis Market, by Treatment Regimen

  • 10.1. Drug Resistant Treatment
    • 10.1.1. Extensively Drug Resistant
    • 10.1.2. Multidrug Resistant
  • 10.2. Drug Susceptible Treatment

11. Mycobacterium Tuberculosis Market, by End User

  • 11.1. Clinics
  • 11.2. Hospitals
  • 11.3. Laboratories
  • 11.4. Research Institutes

12. Mycobacterium Tuberculosis Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Mycobacterium Tuberculosis Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Mycobacterium Tuberculosis Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Mycobacterium Tuberculosis Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Mycobacterium Tuberculosis Market

17. China Mycobacterium Tuberculosis Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Molecular Inc.
  • 18.6. Actiza Pharmaceutical Private Limited
  • 18.7. Anuh Pharma Ltd.
  • 18.8. AstraZeneca PLC
  • 18.9. Bayer AG
  • 18.10. Becton, Dickinson and Company
  • 18.11. bioMerieux SA
  • 18.12. Cadila Healthcare Ltd.
  • 18.13. CapitalBio
  • 18.14. Care Formulation Labs Private Limited
  • 18.15. Cepheid, Inc.
  • 18.16. Cipla Ltd.
  • 18.17. DaAN Gene Company
  • 18.18. Eiken Chemical Co., Ltd.
  • 18.19. GlaxoSmithKline plc
  • 18.20. Hain Lifescience GmbH
  • 18.21. Hetero Labs Ltd.
  • 18.22. Hologic, Inc.
  • 18.23. Johnson & Johnson
  • 18.24. Lupin Limited
  • 18.25. Macleods Pharmaceuticals Ltd.
  • 18.26. Merck & Co., Inc.
  • 18.27. Molbio Diagnostics Private Limited
  • 18.28. Novartis AG
  • 18.29. Otsuka Pharmaceutical Co., Ltd.
  • 18.30. Pfizer Inc.
  • 18.31. QIAGEN N.V.
  • 18.32. Roche Diagnostics International AG
  • 18.33. Sandoz International GmbH
  • 18.34. Sanofi S.A.
  • 18.35. Serum Institute of India Pvt. Ltd.
  • 18.36. Thermo Fisher Scientific Inc.
  • 18.37. Titan Biotech Limited
  • 18.38. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY FIRST LINE DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY FIRST LINE DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY FIRST LINE DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY SECOND LINE DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY SECOND LINE DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY SECOND LINE DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY CULTURE TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY CULTURE TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY CULTURE TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MICROSCOPY TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MICROSCOPY TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MICROSCOPY TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY LAMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY LAMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY LAMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY XPERT MTB RIF, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY XPERT MTB RIF, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY XPERT MTB RIF, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY SKIN TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY SKIN TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY SKIN TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY EXTENSIVELY DRUG RESISTANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY EXTENSIVELY DRUG RESISTANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY EXTENSIVELY DRUG RESISTANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MULTIDRUG RESISTANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MULTIDRUG RESISTANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MULTIDRUG RESISTANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG SUSCEPTIBLE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG SUSCEPTIBLE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG SUSCEPTIBLE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. GCC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GCC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 148. GCC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. GCC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 150. GCC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 151. GCC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 152. GCC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GCC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. G7 MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. G7 MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 172. G7 MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. G7 MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 174. G7 MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 175. G7 MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 176. G7 MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. G7 MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. NATO MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. NATO MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 180. NATO MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. NATO MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 182. NATO MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 183. NATO MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 184. NATO MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. NATO MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)